by Overview:
Sweating is the body’s way of cooling itself when it becomes hot. Whereas in some people the nervous system sends faulty signals that cause sweat glands to become overactive. This is called primary hyperhidrosis. It affects the palms, feet, armpits and groin areas. People who sweat excessively often feel embarrassed, anxious and stressed, which can interfere with work, social activities and personal relationships. Excessive sweating can also cause a bad odor when bacteria break down the sweat. The condition is very common, and it can occur all over the body, including the face, hands, feet and underarms. It can affect a person’s quality of life and cause embarrassment. The first step in treating hyperhidrosis is a physical exam. Surgical treatments for hyperhidrosis are rare, a child’s dermatologist will discuss, if it is recommended.
Market Dynamics:
Increasing acquisitions by key players are estimated to augment growth of the global hyperhidrosis treatment market during the forecast period. For instance, a new dermatology product Sofpironium bromide gel, from Brickell Biotech was acquired by Botanix Pharmaceutical, in May 2022. This medicine has been developed for treating primary axillary hyperhidrosis that can cause excessive underarm sweating. Moreover, increasing side effects of botox and rising cost are anticipated to restrain growth of the global hyperhidrosis treatment market during the forecast period.
Impact of COVID-19:
The pandemic was first identified in 2019. In 2020, it was declared as a global public health emergency by the WHO. The pandemic will also hamper the growth of several sectors such as automobiles, electronics, healthcare, and many more. The pandemic also had a huge impact on the research and development of medicines. As many organizations and pharmaceuticals were focusing on the development of drugs, vaccines, or treatments options. This restrained the growth of the global Hyperhidrosis Treatment Market. However, the market is estimated to witness growth as many restrictions have now been relaxed and the number of COVID-19 cases have also decreased.
Key Takeaways:
The global hyperhidrosis treatment market is expected to witness high growth, exhibiting CAGR of 6.20 % over the forecast period, due to increasing agreements among key players. For instance, Amgen and Kyowa Kirin Co. Ltd., signed a contract in June 2021, for developing and distributing a completely human monoclonal Hyperhidrosis Treatment KHK4083. This collaboration will help the company is growing.
North America is anticipated to witness significant growth in the global hyperhidrosis treatment market during the forecast period, due to growing incidences of hyperhidrosis and increasing prevalence of obesity.
Key players operating in the global hyperhidrosis treatment market are Dr. August Wolff GmbH, Allergan PLC, TheraVida, Dermadry Laboratories lnc., Revance Therapeutics, Inc., Cynosure, Sesderma, Brickell Biotech Inc., Dermira Inc., Ulthera Inc, Miramar Labs, Inc., GlaxoSmithKline PLC, and Miramar Labs, Inc.
